<DOC>
	<DOCNO>NCT02786979</DOCNO>
	<brief_summary>The objective evaluate efficacy safety combination beraprost aspirin prevention arteriosclerosis progress type 2 diabetes mellitus patient .</brief_summary>
	<brief_title>Efficacy Safety Dorner Tablets Aspirin Prevention Arteriosclerosis Progress Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Patients diagnose type 2 diabetes mellitus ; Patients intimamedia thickness ( IMT ) carotid artery â‰¥1.1 mm least one side ; Patients result aspartate aminotransferase , alanine aminotransferase , serum creatinine 1.5 time high upper limit normal ; Patients cardio cerebral vascular event within 3 month , include nonfatal myocardial infarction , stable unstable angina pectoris , nonfatal cerebral ischemic hemorrhagic stroke ; Patients systolic blood pressure &lt; 160 mmHg , diastolic blood pressure &lt; 100 mmHg , glycated hemoglobin ( HbA1c ) &lt; 8.0 % ; Patients take medication antithrombotic antiplatelet effect within 3 month ; Patients peptic ulcer active alimentary tract hemorrhage ; Patients know allergy prostacycline nonsteroid medication ; Patients pregnant , breast feeding , plan pregnant ; Patients attend attend clinical study within 3 month ;</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>beraprost</keyword>
	<keyword>Aspirin</keyword>
</DOC>